Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

Cancer immunotherapy in patients with brain metastases

(2018) Salvatore Caponnetto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

(2018) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

(2018) Daichi Fujimoto et al.   LUNG CANCER

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

(2018) Koichi Sato et al.   LUNG CANCER

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer

(2018) Renaud Sabatier et al.   Journal of Geriatric Oncology

Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions

(2018) Dianne Hartgerink et al.   Frontiers in Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

(2017) Marco Donia et al.   EUROPEAN JOURNAL OF CANCER

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases

(2017) Kamran A. Ahmed et al.   JOURNAL OF NEURO-ONCOLOGY

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

(2017) Shunsuke Teraoka et al.   Journal of Thoracic Oncology

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

(2017) Kari Chansky et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

(2017) Elizabeth Dudnik et al.   LUNG CANCER

Real-world data on nivolumab treatment of non-small cell lung cancer

(2016) O.T. Brustugun et al.   ACTA ONCOLOGICA

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

(2015) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

(2015) Jonathan D. Schoenfeld et al.   Journal for ImmunoTherapy of Cancer

Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress

(2012) Kevin S. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

(2012) Jonathan P. S. Knisely et al.   JOURNAL OF NEUROSURGERY

Epidemiology of Brain Metastases

(2011) Lakshmi Nayak et al.   Current Oncology Reports

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS